All patients included in the study were diagnosed with prostate adenocarcinoma, with the following distribution according to the Gleason score (GS): GS 6 24.7%, GS 7 36.6%, GS 8 22.3%, GS 9 13.1%, and GS 10 3.0%, while the percentage of patients included in the group in which the initial PSA value was over 20 ng/mL was 57.9% (187 patients) (Table 2). This evidence concerns the gene KLK3 and prostate adenocarcinoma.